

# Zongmei Zhou

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6384500/zongmei-zhou-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61

papers

550

citations

14

h-index

20

g-index

73

ext. papers

844

ext. citations

4

avg, IF

3.37

L-index

#	Paper	IF	Citations
61	Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. <i>Cancer</i> , <b>2011</b> , 117, 5423-31	6.4	57
60	Dosimetrics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 269	5.3	39
59	Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. <i>Annals of Thoracic Surgery</i> , <b>2014</b> , 98, 513-9	2.7	39
58	Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 330-7	4	36
57	The Impact of Postoperative Conformal Radiotherapy After Radical Surgery on Survival and Recurrence in Pathologic T3N0M0 Esophageal Carcinoma: A Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1143-1151	8.9	23
56	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1178-1185	13.4	23
55	Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy. <i>Oncologist</i> , <b>2016</b> , 21, 1530-1537	5.7	22
54	Prediction of Radiation Pneumonitis With Dose Distribution: A Convolutional Neural Network (CNN) Based Model. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1500	5.3	21
53	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1565-73	8.9	20
52	Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 399-406	3.2	16
51	A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 104, 1718-1724	2.7	15
50	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. <i>Radiation Oncology</i> , <b>2019</b> , 14, 48	4.2	15
49	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 2890-2898	3.1	14
48	Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 597-604	3.2	14
47	Deep Learning Improved Clinical Target Volume Contouring Quality and Efficiency for Postoperative Radiation Therapy in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1192	5.3	12
46	Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. <i>Oncologist</i> , <b>2020</b> , 25, e701-e708	5.7	11
45	Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy--retrospective analysis of 203 cases. <i>BMC Cancer</i> , <b>2015</b> , 15, 715	4.8	11

44	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. <i>Oncotarget</i> , <b>2016</b> , 7, 55211-55221	3.3	11
43	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. <i>Radiation Oncology</i> , <b>2019</b> , 14, 106	4.2	10
42	A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. <i>BMC Cancer</i> , <b>2019</b> , 19, 397	4.8	10
41	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 140, 159-166	5.3	10
40	Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1431-1440	3.2	9
39	MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. <i>BioMed Research International</i> , <b>2017</b> , 2017, 6501385	3	9
38	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. <i>BMC Cancer</i> , <b>2020</b> , 20, 144	4.8	8
37	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. <i>Oncotarget</i> , <b>2017</b> , 8, 41102-41112	3.7	8
36	Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , <b>2017</b> , 12, 195	4.2	7
35	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1918070	10.4	7
34	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. <i>Journal of Cancer</i> , <b>2019</b> , 10, 1985-1990	4.5	6
33	The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC). <i>Oncotarget</i> , <b>2017</b> , 8, 48922-48929	3.3	6
32	A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. <i>BMC Cancer</i> , <b>2020</b> , 20, 130	4.8	5
31	A deep learning method for producing ventilation images from 4DCT: First comparison with technegas SPECT ventilation. <i>Medical Physics</i> , <b>2020</b> , 47, 1249-1257	4.4	5
30	Managing a radiotherapy center safely and efficiently using risk-adaptive strategies during coronavirus disease pandemic: Experience from national cancer center of China. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 148, 243-244	5.3	4
29	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1499	5.3	4
28	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. <i>Acta Oncologica</i> , <b>2021</b> , 60, 627-634	3.2	4
27	Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 814-823	3.2	4

26	CHST15 promotes the proliferation of TE-1 cells via multiple pathways in esophageal cancer. <i>Oncology Reports</i> , <b>2020</b> , 43, 75-86	3.5	3
25	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 156, 244-250	5.3	3
24	Radiation pneumonitis complicated by <i>Pneumocystis carinii</i> in patients with thoracic neoplasia: a clinical analysis of 7 cases. <i>Cancer Communications</i> , <b>2019</b> , 39, 47	9.4	2
23	Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial. <i>Radiation Oncology</i> , <b>2020</b> , 15, 155	4.2	2
22	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 901	4.8	2
21	Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China. <i>Radiation Oncology</i> , <b>2021</b> , 16, 102	4.2	2
20	Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 799-806	3.2	2
19	Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic Carcinoma. <i>Thoracic and Cardiovascular Surgeon</i> , <b>2020</b> , 68, 440-445	1.6	2
18	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. <i>BMC Cancer</i> , <b>2020</b> , 20, 278	4.8	2
17	Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2021</b> , 33, 53-60	3.8	2
16	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	2
15	Primary intrathoracic liposarcoma: a clinical analysis of 31 cases. <i>Cancer Communications</i> , <b>2019</b> , 39, 15	9.4	1
14	Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 9643-9653	3.6	1
13	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 877	4.8	1
12	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1831-1840	3.2	1
11	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. <i>Lung Cancer</i> , <b>2021</b> , 157, 116-123	5.9	1
10	Prospective Exploratory Study of the Clinical Significance of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Exposed to Prophylactic Cranial Irradiation. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 575394	5.3	1
9	Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. <i>Oncologist</i> , <b>2021</b> , 26, e2151-e2160	5.7	1

8	Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1	3.1	1
7	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 781340	5.3	0
6	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211061948	5.4	0
5	Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. <i>Tumori</i> , <b>2021</b> , 107, 407-415	1.7	0
4	Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 7076-7086	3.1	0
3	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.. <i>Clinical Medicine Insights: Oncology</i> , <b>2022</b> , 16, 11795549221080347	1.8	0
2	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 618776	5.3	
1	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma.. <i>Radiation Oncology</i> , <b>2022</b> , 17, 58	4.2	